Sonrotoclax

Sonrotoclax

Chemical structure of Sonrotoclax

Sonrotoclax is a small molecule inhibitor that targets the B-cell lymphoma 2 (BCL-2) protein, which is involved in the regulation of apoptosis, or programmed cell death. It is being investigated for its potential use in the treatment of various types of cancer, particularly those that are resistant to conventional therapies.

Mechanism of Action

Sonrotoclax functions by binding to the BCL-2 protein, a member of the BCL-2 family of proteins that regulate cell death. BCL-2 is an anti-apoptotic protein, meaning it prevents cells from undergoing apoptosis. In many cancers, BCL-2 is overexpressed, allowing cancer cells to evade the normal cell death process and continue to proliferate. By inhibiting BCL-2, Sonrotoclax promotes apoptosis in cancer cells, thereby reducing tumor growth.

Clinical Development

Sonrotoclax is currently undergoing clinical trials to evaluate its efficacy and safety in patients with various types of cancer, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). These trials aim to determine the optimal dosing regimen and to identify any potential side effects associated with the drug.

Potential Benefits

The development of Sonrotoclax is particularly significant for patients with cancers that have developed resistance to existing treatments. By specifically targeting the BCL-2 protein, Sonrotoclax offers a novel approach to cancer therapy that could improve outcomes for patients with difficult-to-treat malignancies.

Side Effects

As with many cancer therapies, Sonrotoclax may cause side effects. Commonly reported side effects include nausea, fatigue, and neutropenia. Ongoing clinical trials are focused on further characterizing the safety profile of Sonrotoclax and managing any adverse effects that arise during treatment.

Related Pages

• BCL-2 family
• Apoptosis
• Chronic lymphocytic leukemia
• Non-Hodgkin lymphoma
• Cancer treatment